Log in

BSX BOSTON SCIENTIFIC CORP NYSE · United States

BOSTON SCIENTIFIC CORP (BSX) news

Latest BOSTON SCIENTIFIC CORP news

We have not published a story on BOSTON SCIENTIFIC CORP yet. When there is news, it will appear here.

BOSTON SCIENTIFIC CORP annual financials

LineFY2025FY2024
Research and development$2.05 billion$1.61 billion
Net income (loss)$2.89 billion$1.85 billion
Cash from operations$4.53 billion$3.44 billion
Cash and equivalents$1.97 billion$414.0 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $539.0 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about BOSTON SCIENTIFIC CORP

What is the ticker symbol of BOSTON SCIENTIFIC CORP?

BOSTON SCIENTIFIC CORP trades under the ticker BSX on NYSE.

Where is BOSTON SCIENTIFIC CORP listed?

BOSTON SCIENTIFIC CORP is listed on NYSE.

Which country or territory is BOSTON SCIENTIFIC CORP listed under?

Our directory records BOSTON SCIENTIFIC CORP under United States.

Does aibio.space cover BOSTON SCIENTIFIC CORP?

aibio.space lists BOSTON SCIENTIFIC CORP among 2,820 public biotech companies and publishes its news here as stories appear.

Is BOSTON SCIENTIFIC CORP profitable?

BOSTON SCIENTIFIC CORP reported net income of $2.89 billion for the fiscal year ended Dec 31, 2025, and generated $4.53 billion of cash from operations, per its annual report to the SEC.

How much does BOSTON SCIENTIFIC CORP spend on research and development?

$2.05 billion in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does BOSTON SCIENTIFIC CORP have?

$539.0 million in cash at Jun 30, 2026, per its 10-Q.

Which other companies' news mentions BOSTON SCIENTIFIC CORP?

BOSTON SCIENTIFIC CORP is named in 1 of our story about other companies, most recently: "Elutia closes $88 million sale of BioEnvelope business to Boston Scientific" (Oct 7, 2025). Source.

How can I follow BOSTON SCIENTIFIC CORP (BSX) news?

Press Follow on this page to add BOSTON SCIENTIFIC CORP to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming BOSTON SCIENTIFIC CORP so far, in Mergers.

Investor discussion: BOSTON SCIENTIFIC CORP

Members talk about BOSTON SCIENTIFIC CORP (BSX). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at BOSTON SCIENTIFIC CORP, newest first. Each line links the filing it comes from.

  1. Legal

    Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source

  2. Distress

    Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NYSE:BSX on TradingView.

Listing details

BOSTON SCIENTIFIC CORP is a public biotech or pharmaceutical company listed on NYSE under the ticker BSX, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
BOSTON SCIENTIFIC CORP
Ticker
BSX
Listing
NYSE
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.